Overview

Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of ASK120067 in Locally Advanced and Metastatic Non Small Cell Lung Cancer

Status:
Recruiting
Trial end date:
2021-08-01
Target enrollment:
Participant gender:
Summary
ASK120067 Tablets is a Epidermal Growth Factor Receptor (EGFR) mutation selective Tyrosine Kinase Inhibitor which can efficient suppress the EGFR T790M drug-resistant mutation tumor cell in Xenograft mouse model. This study aims at local advanced or metastatic non-small cell lung cancer patients with T790M drug-resistant mutation.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Jiangsu Aosaikang Pharmaceutical Co., Ltd.